SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses the launch of the $DOJE ETF, with some anticipating significant price movement. Talk centers around potential accumulation strategies and whether the ETF will trigger a major rally, although the launch may be delayed. There's also discussion around Dogecoin's long-term value and comparisons to other cryptocurrencies.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies, emphasizing its strength and long-term vision, particularly after the CEO departure. Discussions highlight the token as Solana's first ETF, with many proclaiming it as the best ETF ever. The community is focused on accumulation, anticipating a significant move.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as traders anticipate Phase 3 data for its lead drug, efzofitimod, in mid-September, creating a high-stakes binary event. The community is buzzing with debate around the trial's design, potential outcomes, and the influence of figures like Martin Shkreli, with some expecting a short squeeze if results are positive. Bullish sentiment is fueled by recent analyst ratings and commercial hires, while bears point to past trial data and high implied volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid heated discussions around the political motivations behind a recent tragedy, sparking intense debate within the community.  Users are clashing over affiliations and broader cultural grievances, with some pointing fingers and others calling for unity. The conversation highlights the deep divisions and sensitivities surrounding the symbol and its association with political figures.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential volatility catalysts, including upcoming economic data and geopolitical tensions. Community members are weighing the potential for a market correction against the effects of contango on the ETF. Some traders are using UVIX to hedge long positions or speculating on short-term price movements.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as the stock experiences volatility amidst analyst upgrades and price target adjustments, leading to community debate on its near-term direction. Discussions revolve around recent price drops being potential profit-taking opportunities or possible manipulation, while others point to strong data center growth prospects and AI networking as long-term bullish factors. Community members are actively trading options and debating entry points, particularly around key technical levels.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community speculates on potential rallies and discusses strategies to push the price higher, with some eyeing the possibility of revisiting all-time highs. Community members are actively sharing bullish sentiments and engaging in meme-based discussions, while also debating the token's potential within the broader meme coin landscape, comparing it to other popular cryptocurrencies like DOGE.X and SHIB.X.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking community discussion about its potential impact and whether it signals a true turning point or further dilution. Community members are actively trading the stock, anticipating significant price movement based on the low float and upcoming conference, with some looking for a short squeeze. The stock is also being compared to other high-flying low floaters.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid discussions about its price action compared to other meme coins like Dogecoin, with some community members expressing frustration over its lack of upward momentum. Some are pointing to the potential for a breakout while others are calling it a scam. The community is also closely watching for any news regarding potential developments and market expansions.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as traders assess Bitcoin's potential near all-time highs and its impact on leveraged ETFs. Community discussions revolve around market volatility, technical analysis, and the broader implications of economic policies. Concerns about potential market corrections and the influence of external factors such as political events are also driving interest in BITX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

Novo Nordisk (NVO) reached $54.87 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

Equity

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Is NVO's Major Restructuring Plan an Indication to Sell the Stock?

Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.

Novo Nordisk shares&nbsp;climbed 0.6% in&nbsp;early premarket trading on Wednesday after the world’s most valuable drugmaker announced plans to cut 9,000 jobs and forecast billions in annual savings, even as it lowered its profit outlook for the third time this year.The Danish firm behind blockbuster obesity drug Wegovy and diabetes treatment Ozempic said it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark.The restructuring is expected to save 8 billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas.&nbsp;“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well,” newly appointed Chief Executive Officer Mike Doustdar said in a statement.The overhaul is accompanied by one-off restructuring costs of 9 billion crowns in the third quarter, including impairment charges, which are partially offset by savings of 1 billion crowns in the fourth quarter.&nbsp;Novo now expects operating profit growth of 4%–10% this year at constant exchange rates, down from 10–16% forecast in August and as high as 27% projected in February.“Sometimes the hardest decisions are the right ones for the future we’re building,” Doustdar&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7371410309493846016/">said in a LinkedIn post</a>. “This is the right thing to do for the long-term success of Novo Nordisk.”Novo has already frozen hiring for non-critical roles and withdrawn offers to some new hires.&nbsp;The shake-up follows a sharp slowdown in growth, with the company losing market share in the U.S. obesity market to Eli Lilly and facing pressure from compounding pharmacies that are allowed to make copycat versions of Wegovy due to supply shortages.The company, valued at about $650 billion at its peak last year, saw $70 billion wiped off its market capitalization in July after a profit warning and the appointment of Doustdar as CEO.Novo said it will report its nine-month results and provide a fresh outlook for 2025 on Nov. 5.On Stocktwits, retail sentiment for Novo Nordisk was ‘bearish’&nbsp;heading into Wednesday’s market open.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s stock</a> has declined nearly 36% so far in 2025.($1=6.38 Danish krone)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Why Is Novo Nordisk’s Stock Rising Premarket Today?

The Danish drugmaker said an overhaul will save 8 billion crowns annually by 2026, but one-off restructuring costs will drag 2025 operating profit growth down to 4–10% from as much as 27% previously projected.

The Institute for Clinical and Economic Review (ICER) determined on Tuesday that Novo Nordisk (NVO) and Eli Lilly and Co.’s (LLY) weight loss drugs are cost-effective, a judgment that is a “win” for the two companies, according to Bank of America.The ICER <a target="_blank" rel="noopener noreferrer nofollow" href="https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf">released</a> a draft report assessing the comparative clinical effectiveness and value of Novo’s Semaglutide and Lilly’s Tirzepatide weight loss drugs for obesity management on Tuesday and judged oral Semaglutide, injectable Semaglutide, and injectable Tirzepatide as cost-effective. The firm estimated net prices of $6,830 for Semaglutide and $7,973 for Tirzepatide.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_1_58_02_PM_png_608eca0732.webp" alt="LLY's Sentiment Meter and Message Volume as of 1:58 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>LLY's Sentiment Meter and Message Volume as of 1:58 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment on <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed in ‘bearish’ territory, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:574/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_1_59_11_PM_png_ce8ef38022.webp" alt="NVO's Sentiment Meter and Message Volume as of 1:59 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="574" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 1:59 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure> ICER, however, flagged certain affordability concerns. ‘We estimate that fewer than 1% of eligible patients could be treated at current and assumed net prices….This raises serious concerns about affordability,” it said.The firm also noted that it has evidence demonstrating greater weight loss with Lilly’s Tirzepatide than Novo’s Semaglutide. However, in the absence of more details regarding the cardiovascular effects of the two drugs, it considers treatment with Tirzepatide compared with Semaglutide to be “promising but inconclusive.”The firm also noted that oral Semaglutide resulted in slightly lower amounts of weight loss compared to injectable Semaglutide, but provided the uncertainty regarding cardiovascular benefits, judged oral Semaglutide to be “comparable or worse” than injectable Semaglutide.ICER will hold a public meeting on the draft report on November 13, after which it will issue a final report. The findings within the firm’s draft report should not be interpreted as its conclusions, the firm said.BofA views the analysis as "an important and necessary step" toward securing better coverage from employers and payers for GLP-1 category weight loss drugs, according to TheFly. The analyst kept a ‘Buy’ rating and $900 price target on Eli Lilly shares, representing an upside of nearly 22% from Lilly’s closing price on Monday.While LLY stock is down by 3% this year, NVO stock is down 37%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hedge-fund-reportedly-prepares-to-launch-board-fight-at-orasure-technologies/chwKOS6Rdtq">Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’

BofA views the analysis as "an important and necessary step" toward securing better coverage from employers and payers for GLP-1 category weight loss drugs, according to TheFly.

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVO Novo Nordisk A/S